Decartes-08
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthaenia Gravis
Conditions
Myasthaenia Gravis
Trial Timeline
May 6, 2025 → Sep 30, 2027
NCT ID
NCT06799247About Decartes-08
Decartes-08 is a phase 3 stage product being developed by Cartesian Therapeutics for Myasthaenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06799247. Target conditions include Myasthaenia Gravis.
What happened to similar drugs?
0 of 1 similar drugs in Myasthaenia Gravis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06799247 | Phase 3 | Recruiting |
Competing Products
1 competing product in Myasthaenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| efgartigimod administration | Argenx | Phase 3 | 44 |